SCHEMBL2540657

SCHEMBL2540657

N#Cc1cc(F)c(N)c(F)c1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EGLN2 Q96KS0 3/20 0.41
KHK P50053 1/20 0.36
TRPV4 Q9HBA0 3/20 0.36
TTR P02766 2/20 0.36
ALB P02768 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
HDAC1 Q13547 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
HTT P42858 1/20 0.34
KIF11 P52732 1/20 0.34
CUL4A Q13619 1/20 0.34
VCAM1 P19320 1/20 0.33
EEF2K O00418 1/20 0.33
ADRB2 P07550 1/20 0.33
ADRB1 P08588 1/20 0.33
MAP4K4 O95819 1/20 0.33
HDAC8 Q9BY41 1/20 0.32
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30418928 0.88 EGLN2 (0.38) EGLN2KHKTRPV4TTRALB
SCHEMBL2437496 0.88 EGLN2 (0.38) EGLN2KHKTRPV4TTRALB
SCHEMBL15321404 0.84 EGLN2 (0.38) EGLN2KHKTTRALBHTT
SCHEMBL10120595 0.84 CA1 (0.44) EGLN2KHKVCAM1
SCHEMBL14247428 0.84 MEN1 (0.48) EGLN2KHKTTRALBMEN1
SCHEMBL1997670 0.84 TTR (0.48) EGLN2KHKTRPV4TTRALB
SCHEMBL3176865 0.81 KIF11 (0.46) EGLN2TRPV4KIF11CUL4ATSHR
SCHEMBL29104000 0.80 ALDH1A1 (0.41) EGLN2MEN1KMT2AHTTTSHR
SCHEMBL15173739 0.80 HTT (0.40) EGLN2TTRALBHTTADRB2
SCHEMBL16411008 0.78 MAP2K1 (0.40) HDAC1HDAC6HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108947782-B Bromofluoride multi-substituted benzaldehyde derivative and preparation method thereof 上海罕道医药科技有限公司 2021-08-24 CN claimed
US-4883609-A LIQUID CRYSTALS SEIKO EPSON CORPORATION (JP) 1989-11-28 US claimed
JP-3038572-A None JP disclosed
WO-2026101423-A1 PHOTOSWITCHABLE CHEMICAL INDUCED DIMERIZATION SYSTEMS FOR CONTROL OF CELLULAR ACTIVITIES WITH LIGHT WU YAOWEN (SE) 2026-05-15 WO disclosed
CN-115197131-B Azo 2-aminonicotinic acid benzyl ester derivative and preparation method and application thereof 华东理工大学 2024-12-03 CN disclosed
US-12071404-B2 Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides UCB PHARMA GMBH (DE) 2024-08-27 US disclosed
EP-3822274-B1 SYNTHETIC INTERMEDIATES USEFUL FOR PREPARING SUBSTITUTED AMINOPURINE COMPOUNDS SIGNAL PHARM LLC (US) 2024-03-06 EP disclosed
US-11820746-B2 Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides UCB PHARMA GMBH (DE) 2023-11-21 US disclosed
US-20230348384-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides UCB PHARMA GMBH (DE) 2023-11-02 US disclosed
US-20230158035-A1 SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH SIGNAL PHARM LLC (US) 2023-05-25 US disclosed
US-20230150998-A1 COMPOUNDS AS GLP-1R AGONISTS Terns, Inc. 2023-05-18 US disclosed
US-5030382-A Liquid crystals SEIKO EPSON CORPORATION (JP) 1991-07-09 US disclosed
JP-H0338572-A PYRIMIDINE DERIVATIVE SEIKO EPSON CORP 1991-02-19 JP disclosed
EP-0391591-A2 Pyrimidine derivative and liquid crystal composition incorporating the same SEIKO EPSON CORPORATION (JP) 1990-10-10 EP disclosed
EP-0390329-A1 Pyrimidine derivative SEIKO EPSON CORPORATION (JP) 1990-10-03 EP disclosed
US-4883609-A LIQUID CRYSTALS SEIKO EPSON CORPORATION (JP) 1989-11-28 US disclosed
US-4873357-A Trifluoro acetyl-cyano-aniline intermediates for dopamine-βhydroxylase inhibitors SMITHKLINE BECKMAN CORPORATION (US) 1989-10-10 US disclosed
EP-0317175-A2 Pyrimidine derivatives SEIKO EPSON CORPORATION (JP) 1989-05-24 EP disclosed
US-4719223-A ENZYME INHIBITORS, HYPOTENSIVE, CARDIOTONIC DIURETIC SMITHKLINE BECKMAN CORPORATION (US) 1988-01-12 US disclosed
EP-0221778-A2 Dopamine-beta-hydroxylase inhibitors SMITHKLINE BECKMAN CORPORATION (US) 1987-05-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11820746-B2 Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides GPR17, GPR18, GPR27 EGLN2 1702/4885KHK 4362/4885TRPV4 285/4885
US-20230348384-A1 Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides GPR17, GPR18, GPR27 EGLN2 1702/4885KHK 4362/4885TRPV4 285/4885
US-20230158035-A1 SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH TPMT, MGMT, TYMP EGLN2 1255/4885KHK 2906/4885TRPV4 4861/4885
US-12071404-B2 Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides GPR17, GPR18, GPR27 EGLN2 1702/4885KHK 4362/4885TRPV4 285/4885
US-20230150998-A1 COMPOUNDS AS GLP-1R AGONISTS GLP1R, GIPR, GCGR EGLN2 1804/4885KHK 1877/4885TRPV4 703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.